What is Zacks Research's Forecast for CLB FY2026 Earnings?

Key Points

• Zacks Research raised Core Laboratories’ FY2026 EPS forecast to $0.62 from $0.57, above the broader consensus estimate of $0.53. It also projects FY2027 EPS of $0.77.
• Core Laboratories’ latest quarterly results beat expectations on earnings, reporting $0.11 EPS versus the $0.09 consensus, although revenue fell 4.3% year over year to $124.61 million.
• Analyst sentiment has improved, with Johnson Rice upgrading the stock to “Buy”; MarketBeat reports a “Moderate Buy” consensus and an average price target of $21, compared with a recent price of $12.67.

Core Laboratories Inc. (NYSE:CLB - Free Report) - Investment analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for shares of Core Laboratories in a research report issued to clients and investors on Wednesday, August 19th. Zacks Research analyst Team now expects that the oil and gas company will earn $0.62 per share for the year, up from their prior estimate of $0.57. The consensus estimate for Core Laboratories' current full-year earnings is $0.53 per share. Zacks Research also issued estimates for Core Laboratories' Q3 2027 earnings at $0.16 EPS, FY2027 earnings at $0.77 EPS and Q2 2028 earnings at $0.31 EPS.

A number of other brokerages have also recently commented on CLB. Johnson Rice upgraded shares of Core Laboratories from a "hold" rating to a "buy" rating and set a $21.00 target price on the stock in a report on Thursday, August 13th. Wall Street Zen upgraded shares of Core Laboratories from a "sell" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings raised shares of Core Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Core Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $21.00.

Core Laboratories Price Performance

CLB opened at $12.67 on Thursday. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41. The company has a market cap of $581.21 million, a price-to-earnings ratio of 22.62, a price-to-earnings-growth ratio of 3.02 and a beta of 1.03. The stock has a fifty day simple moving average of $11.55 and a two-hundred day simple moving average of $14.52. Core Laboratories has a 12-month low of $9.79 and a 12-month high of $20.36.

Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $124.61 million during the quarter, compared to analysts' expectations of $126.26 million. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The firm's revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 EPS. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS.

Hedge Funds Weigh In On Core Laboratories

Large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Core Laboratories by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company's stock worth $418,000 after purchasing an additional 1,170 shares in the last quarter. American Century Companies Inc. increased its stake in Core Laboratories by 14.3% during the 2nd quarter. American Century Companies Inc. now owns 133,033 shares of the oil and gas company's stock valued at $1,533,000 after purchasing an additional 16,677 shares in the last quarter. Quantbot Technologies LP raised its holdings in Core Laboratories by 343.7% in the second quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company's stock worth $202,000 after buying an additional 13,571 shares during the last quarter. Sei Investments Co. purchased a new position in Core Laboratories in the second quarter worth about $231,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Core Laboratories by 6.2% in the second quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company's stock worth $207,000 after buying an additional 1,040 shares in the last quarter. Hedge funds and other institutional investors own 97.81% of the company's stock.

Insider Buying and Selling

In related news, CEO Lawrence Bruno bought 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $10.78 per share, with a total value of $53,900.00. Following the completion of the purchase, the chief executive officer owned 262,438 shares in the company, valued at approximately $2,829,081.64. The trade was a 1.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.26% of the company's stock.

Core Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Monday, August 10th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, August 10th. Core Laboratories's payout ratio is 7.14%.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company's portfolio spans two primary service lines: reservoir description and production enhancement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source